{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"49.0","upperLimit":"106.0","value":"53.0"},{"groupId":"OG001","lowerLimit":"52.0","upperLimit":"99.0","value":"59.0"},{"groupId":"OG002","lowerLimit":"45.0","upperLimit":"89.0","value":"54.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"38"},{"groupId":"OG002","value":"34"}],"units":"Participants"}],"description":"PFS time was calculated as the number of days from study day 1 to the date of PD or death, regardless of cause (date of PD or death - study day 1 + 1).","dispersionType":"95% Confidence Interval","groups":[{"description":"Includes the Phase 1 dose-finding groups A, B, and C","id":"OG000","title":"Phase 1"},{"description":"Phase 2 Treatment Group B had 10 mg/m2 of pralatrexate followed the next day by 400 mg/m2 of gemcitabine administered once every 2 weeks. One cycle of pralatrexate and gemcitabine was 4 weeks in duration and consisted of 2 doses each of pralatexate and gemcitabine.","id":"OG001","title":"Phase 2 - Group B"},{"description":"Phase 2 Treatment Group C had 15 mg/m2 of pralatrexate followed 1 hour later by 600 mg/m2 of gemcitabine administered once every 2 weeks. One cycle of pralatrexate and gemcitabine was 4 weeks in duration and consisted of 2 doses each of pralatrexate and gemcitabine.","id":"OG002","title":"Phase 2 - Group C"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"Response assessments were performed no less than every 3 cycles in the Phase 1 part of the study and every 8 weeks (± 1 week) in the Phase 2a part of the study","title":"Progression-free Survival (PFS) Time","type":"SECONDARY","unitOfMeasure":"days"}